Clinical trials represent a crucial stage in the research and development process of a new drug because only once this process is completed can the product be brought to market. However, there are numerous challenges to be faced as the product often struggles to reach the market at due to difficulties in planning, selecting participating centers, recruiting patients and managing resources. The feasibility phase of a new clinical trial plays a key role in the clinical trial process, as it allows a thorough preliminary assessment of participating centers to be conducted in relation to the feasibility of conducting a trial itself. The data and information provided by the centers at this stage are crucial for the company in order to achieve its goals and bring the study to completion. One of the most relevant data concerns the number of potentially enrollable patients provided by the centers. Achieving the company's intended target is often one of the main critical issues. For this reason, this thesis aims, in addition to providing an overview of the feasibility of a new clinical trial, to analyze the data collected by clinical investigators such as Principal Investigator (PI), Sub-Investigator (Sub-I), Study Coordinator (SC), and GSK corporate staff such as Local Delivery Lead (LDL), Local Delivery Lead Manager, People Manager, Site Engagement Leader (SEL), Start Up and Operations Head, and Clinical Operation Director. To this end, two surveys were developed and subsequently analyzed using statistical tools, with the objective of identifying a priori the critical issues present in the process. In a second step, in-depth interviews were conducted with some of the participants in order to gather opinions, investigate experiences, identify critical issues in the processes, and present possible solutions to improve the process itself. In summary, this thesis work aims to optimize the feasibility process by identifying areas of improvement and proposing potential intervention strategies.
La sperimentazione clinica rappresenta una fase cruciale nel processo di ricerca e sviluppo di un nuovo farmaco in quanto, solo una volta completato questo processo, il prodotto può essere messo in commercio. Tuttavia, ci sono numerose sfide da affrontare, poiché spesso il prodotto fatica a raggiungere il mercato a causa di difficoltà nella pianificazione, nella selezione dei centri partecipanti, nel reclutamento dei pazienti e nella gestione delle risorse. La fase di fattibilità di un nuovo studio clinico riveste un ruolo fondamentale nel processo di sperimentazione clinica, poiché consente di condurre una valutazione preliminare approfondita dei centri partecipanti in relazione alla possibilità di condurre uno studio stesso. I dati e le informazioni fornite dai centri in questa fase sono fondamentali per l’azienda al fine di raggiungere gli obiettivi prefissati e portare a termine lo studio. Uno dei dati di maggiore rilevanza riguarda il numero di pazienti potenzialmente arruolabili fornito dai centri. Il raggiungimento del target previsto dall’azienda rappresenta spesso una delle principali criticità. Per tale motivo, questa tesi si propone, oltre a fornire una panoramica sulla fattibilità di un nuovo studio clinico, di analizzare i dati raccolti da ricercatori clinici quali Principal Investigator (PI), Sub-Investigator (Sub-I), Study Coordinator (SC) e da personale aziendale GSK quali Local Delivery Lead (LDL), Local Delivery Lead Manager, People Manager, Site Engagement Leader (SEL), Start Up and Operations Head, e Clinical Operation Director. A tal fine, sono state sviluppate due survey, successivamente analizzate mediante strumenti statistici, con l’obiettivo di identificare a priori le criticità presenti nel processo. In un secondo momento, sono state condotte delle interviste approfondite con alcuni dei partecipanti, al fine di raccogliere opinioni, indagare esperienze, identificare criticità nei processi e presentare possibili soluzioni per migliorare il processo stesso. In sintesi, questo lavoro di tesi mira ad ottimizzare il processo di fattibilità, identificando le aree di miglioramento e proponendo potenziali strategie di intervento.
La fattibilità di un nuovo studio clinico: analisi di dati da ricercatori clinici e personale aziendale per identificare aree di miglioramento
MAGLIO, MIRIAM
2024/2025
Abstract
Clinical trials represent a crucial stage in the research and development process of a new drug because only once this process is completed can the product be brought to market. However, there are numerous challenges to be faced as the product often struggles to reach the market at due to difficulties in planning, selecting participating centers, recruiting patients and managing resources. The feasibility phase of a new clinical trial plays a key role in the clinical trial process, as it allows a thorough preliminary assessment of participating centers to be conducted in relation to the feasibility of conducting a trial itself. The data and information provided by the centers at this stage are crucial for the company in order to achieve its goals and bring the study to completion. One of the most relevant data concerns the number of potentially enrollable patients provided by the centers. Achieving the company's intended target is often one of the main critical issues. For this reason, this thesis aims, in addition to providing an overview of the feasibility of a new clinical trial, to analyze the data collected by clinical investigators such as Principal Investigator (PI), Sub-Investigator (Sub-I), Study Coordinator (SC), and GSK corporate staff such as Local Delivery Lead (LDL), Local Delivery Lead Manager, People Manager, Site Engagement Leader (SEL), Start Up and Operations Head, and Clinical Operation Director. To this end, two surveys were developed and subsequently analyzed using statistical tools, with the objective of identifying a priori the critical issues present in the process. In a second step, in-depth interviews were conducted with some of the participants in order to gather opinions, investigate experiences, identify critical issues in the processes, and present possible solutions to improve the process itself. In summary, this thesis work aims to optimize the feasibility process by identifying areas of improvement and proposing potential intervention strategies.| File | Dimensione | Formato | |
|---|---|---|---|
|
Maglio_Miriam.pdf
accesso aperto
Dimensione
3.74 MB
Formato
Adobe PDF
|
3.74 MB | Adobe PDF | Visualizza/Apri |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/89737